AMGN - European advisory group backs new uses of six medicines

The European Medicines Agency's advisory group CHMP has adopted positive opinions backing extended uses of the following drugs:Amgen's (AMGN) Kyprolis (carfilzomib): in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone or with dexamethasone alone for the treatment of adults with multiple myeloma who have received at least one prior line of therapy.Boehringer Ingelheim's Pradaxa (dabigatran etexilate): new pharmaceutical forms (coated granules and powder and solvent for oral solution) and strengths and new indication for the treatment and prevention of venous thromboembolic events ((VTE)) in pediatric patients from birth to less than 18 years of age.ViiV Healthcare's [(PFE), (GSK), (SGIOF)] Tivicay (dolutegravir): new pharmaceutical form (dispersible tablets) and strength (5 mg) and new indication in combination with other antivirals for the treatment of HIV infection in patients at least four weeks old weighing at least 3 kg.Chiesi Farmaceutici S.p.A.'s Trimbow (beclometasone / formoterol / glycopyrronium bromide) new strength and new

For further details see:

European advisory group backs new uses of six medicines